Winstgevend schreef op 20 mei 2019 16:32:
Meest verrassende statement in de outlook voor de rest van dit jaar:
further clinical trial programs for RUCONEST® in acute treatment
and
prophylaxis of HAE, the development of a
small intravenous liquid version and
new
intramuscular, subcutaneous and intradermal versions of RUCONEST® as well as research
into other routes of administration.
Maar eerst ff Pre-Eclampsia opstarten....... VERY SOON.